1.
Anaerobic storage of red blood cells in a novel additive solution improves in vivo recovery
Dumont LJ, Yoshida T, Herschel L, Dumont D, Waters S, Baker S, AuBuchon JP
Transfusion. 2008;48((S2):):38A.. Abstract No. S101-030M.
2.
A randomized, controlled, 2-period crossover study of recovery and lifespan of radiolabeled autologous 35-day-old red blood cells prepared with a modified s-303 treatment for pathogen inactivation
Cancelas JA, Dumont L, Herschel L, Roger J, Rugg N, Arndt P, Propst M, Laurence L, Sundin D, AuBuchon J
Vox Sanguinis. 2008;95((Suppl 1):):8. Abstract No. 2A-SO1-03.
3.
In vivo and in vitro evaluation of the ONE-STEP LEUKOSEPâ„¢ Filtration System for Red Blood Cells
Rugg N, Cancelas JA, Pratt PG, Gormas JF, Joines A, AuBuchon JP, Herschel L, Rogers J, Zia M, Kandler R
Transfusion. 2006;46((9s):):75A.. Abstract No. SP116.
4.
In vitro evaluation of the ONE-STEP LEUKOSEPâ„¢ Filtration System for Red Blood Cells
Rugg N, Cancelas JA, Pratt PG, Gormas JF, Joines AD, AuBuchon JP, Herschel L, Roger J, Zia M, Spearman M
Transfusion. 2005;45((s3):):70A.. Abstract No. SP131.
5.
Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction
AuBuchon JP, Herschel L, Roger J, Taylor H, Whitley P, Li J, Edrich R, Goodrich RP
Transfusion. 2004;44((s1):):16A-17A.. Abstract No. S47-0301.
6.
Transfusion to blood group A and O patients of group B RBCs that have been enzymatically converted to group O
Kruskall MS, AuBuchon JP, Anthony KY, Herschel L, Pickard C, Biehl R, Horowitz M, Brambilla DJ, Popovsky MA
Transfusion. 2000;40((11):):1290-8.
Abstract
BACKGROUND The transfusion of ABO-incompatible RBCs is the leading cause of fatal transfusion reactions. Group O RBCs, lacking terminal immunodominant A and B sugars to which humans are immunized, are safe for transfusion to persons of any ABO blood group. With the use of a recombinant alpha-galactosidase to remove terminal galactose from group B RBCs, the safety and efficacy of enzyme-converted group-B-to-group-O (ECO) RBC components were studied in transfusion-dependent patients. STUDY DESIGN AND METHODS Twenty-four patients (blood groups A and O) were randomly assigned to receive transfusion(s) of either ECO or control group O RBCs. If a second transfusion was given, the other blood component was administered. RESULTS Twenty-one patients were given ECO RBCs; 18 also underwent control transfusions. One patient received only a small aliquot for RBC survival studies, instead of a full-unit transfusion, because his serum was incompatible with ECO RBCs. No adverse events occurred. Both ECO and control transfusions resulted in appropriate Hb increments and comparable (51)Cr-labeled RBC survival studies. One patient developed a transient, weak-positive DAT, without hemolysis. Two weeks after transfusion, 5 of 19 evaluable ECO RBC recipients had increases in anti-B titers. CONCLUSION ECO RBCs were comparable to group O cells for safety and efficacy in this study. The clinical significance of the increase in anti-B and of occasional serologic incompatibilities with ECO RBCs is unclear. If strategies can be developed to remove A epitopes, enzymatic conversion could be used to create a universal (group O) donor blood supply.
7.
Transfusion of enzymatically converted (group B to group O) red cells to patients: a phase II trial
Kruskall MS, AuBuchon JP, Anthony KY, Herschel L, Pickard C, Biehl R,, et al.,
Transfusion. 1998;38((10S):):86S.. Abstract No. S324.
8.
Recovery and long-term survival of enzyme-converted group O red blood cells after transfusion into patients
AuBuchon JP, Pickard C, Herschel L
Transfusion. 1998;38((10S):):3S.. Abstract No. P9.